INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
SKIN
SUSTAINABILITY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
MEDIA PACK
CONTRIBUTE
Subscribe
INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
SKIN
SUSTAINABILITY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
MEDIA PACK
CONTRIBUTE
SEARCH
SEARCH
advanced search
Dr Benjamin Yerxa
Chief Scientific Officer
Is this your profile?
About
Benjamin Yerxa, PhD, was Chief Scientific Officer at Envisia Therapeutics.
Contributions
OCULAR
IMPROVING OUTCOMES IN OPHTHALMOLOGY VIA SUSTAINED DRUG DELIVERY
Tomas Navratil, Benjamin Maynor and Benjamin Yerxa describe the company’s particle engineering technology and its application in improving the delivery of prostaglandin analogues and anti-VEGF therapy.
Top